Revised SPC: Kaletra (ritonavir, lopinavir) products

SPC has been updated to warn co-administration with fostamatinib (FS) may increase FS metabolite R406 exposure resulting in dose-related ADRs such as hepatotoxicity, neutropenia, hypertension, or diarrhoea If such events occur, there are dose reduction recommendations in FS SPC.

Source:

electronic Medicines compendium